7 completed, 5 active not recruiting, 3 unknown, 1 withdrawn. 5 Phase 1, 5 Phase 3, 4 Early Phase 1, 3 Phase 2, 1 Not applicable.
Follow Stage IIIC Primary Peritoneal Cancer AJCC v7: new trials by email Literature Review of Stage IIIC Primary Peritoneal Cancer AJCC v7 trials Research Report on Stage IIIC Primary Peritoneal Cancer AJCC v7
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Carboplatin, Paclitaxel, Ruxolitinib Phosphate - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Completed | NRG Oncology | 147 | 2016-11-14 | 2025-05-25 |
| Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer Internet-Based Intervention, Quality-of-Life Assessment, Questionnaire Administration - Endometrial Carcinoma, Stage 0 Fallopian Tube Cancer AJCC v7 | Not applicable | Withdrawn | Rutgers, The State University of New Jersey | 2016-07-27 | 2021-04-19 | |
| Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) Carboplatin, Durvalumab, Laboratory Biomarker Analysis - Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7 | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 18 | 2016-07-06 | 2026-06-11 |
| Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7 | Phase 2 | Completed | M.D. Anderson Cancer Center | 31 | 2016-07-05 | 2026-07-07 |
| Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Adavosertib, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 38 | 2016-02-04 | 2026-10-06 |
| Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, BMN 673 - Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 4 | 2015-06-02 | 2022-02-24 |
| Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Epacadostat, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery - Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7 | Early Phase 1 | Completed | National Cancer Institute (NCI) | 17 | 2014-08-25 | 2024-12-13 |
| TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study - Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 50 | 2014-05-20 | 2026-08-28 |
| Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer Carboplatin, Cisplatin, Gemcitabine Hydrochloride - FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer | Phase 1 | Active not recruiting | City of Hope Medical Center | 40 | 2014-05-19 | 2026-03-05 |
| Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Behavioral Dietary Intervention, Compliance Monitoring, Counseling - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Unknown | Gynecologic Oncology Group | 1070 | 2012-06-18 | 2018-02-19 |
| Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Chemotherapy, Propranolol Hydrochloride, Quality-of-Life Assessment - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 32 | 2012-03-09 | 2019-08-29 |
| Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Computed Tomography - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 692 | 2010-09-27 | 2026-05-29 |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Carcinoma, Fallopian Tube Carcinosarcoma | Phase 1 | Completed | National Cancer Institute (NCI) | 431 | 2009-10-28 | 2021-10-20 |
| Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Carboplatin, Ifosfamide, Paclitaxel - Mixed Mesodermal (Mullerian) Tumor, Ovarian Carcinosarcoma | Phase 3 | Unknown | GOG Foundation | 637 | 2009-08-17 | 2021-09-30 |
| Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1560 | 2009-08-11 | 2026-06-02 |
| Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Clinical Observation, Laboratory Biomarker Analysis, Paclitaxel - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Unknown | GOG Foundation | 1157 | 2005-03-21 | 2021-09-30 |
Fallopian Tube Neoplasms (15) · Brenner Tumor (5) · Ovarian Neoplasms (4) · Carcinoma (1) · Carcinosarcoma (1) · Endometrial Neoplasms (1) · Glioblastoma (1) · Uterine Cervical Neoplasms (1)
Adnexal Diseases (16) · Female Urogenital Diseases (16) · Female Urogenital Diseases and Pregnancy Complications (16) · Genital Diseases (16) · Genital Diseases, Female (16) · Genital Neoplasms, Female (16) · Neoplasms (16) · Urogenital Diseases (16) · Urogenital Neoplasms (16) · Fallopian Tube Diseases (15) · Neoplasms by Site (15) · Endocrine System Diseases (8) · Gonadal Disorders (8) · Neoplasms by Histologic Type (8) · Ovarian Diseases (8)
Paclitaxel (9) · Taxes (9) · Carboplatin (8) · Disulfides (5) · Immunoglobulin G (5) · Bevacizumab (4) · 1,2-diaminocyclohexaneplatinum II citrate (3) · Cisplatin (3) · Platinum (3) · Counseling (1) · Doxorubicin (1) · Drug Therapy (1) · Early Intervention, Educational (1) · Educational Status (1) · Gemcitabine (1)
M.D. Anderson Cancer Center (5) · National Cancer Institute (NCI) (5) · GOG Foundation (2) · City of Hope Medical Center (1) · Gynecologic Oncology Group (1) · NRG Oncology (1) · Rutgers, The State University of New Jersey (1)
United States (16) · South Korea (2) · Canada (1)
Shannon N Westin (2) · Amir Jazaeri, MD (1) · Charles N Landen (1) · David Alberts (1) · Joan L Walker (1) · John K Chan (1) · Katherine M Bell-McGuinn (1) · Kunle Odunsi (1) · Lakshmi Nayak (1) · Larry J Copeland (1) · Lois M Ramondetta (1) · Matthew A Powell (1) · Shannon Westin (1) · Sharon Manne (1) · Thanh Dellinger (1)
PMID 32379297, PMID 26933849, PMID 27394382, PMID 31002578, PMID 31708167, PMID 33610319, PMID 35007153, PMID 35357903, PMID 35759733, PMID 36608382, PMID 37185961, PMID 38776484, PMID 39151421
U10CA180868 (6), U10CA027469 (5), P30CA016672 (2), P30CA006516 (1), P30CA015704 (1), P30CA072720 (1), P50CA083639 (1), U01CA062490 (1), U01CA076576 (1), U01CA154967 (1), U10CA101165 (1), U10CA180830 (1), UG1CA189867 (1), UM1CA186709 (1), UM1CA186712 (1)